Traders bought shares of Becton, Dickinson and Company (NYSE:BDX) on weakness during trading on Tuesday following insider selling activity. $71.81 million flowed into the stock on the tick-up and $44.34 million flowed out of the stock on the tick-down, for a money net flow of $27.47 million into the stock. Of all companies tracked, Becton, Dickinson and had the 15th highest net in-flow for the day. Becton, Dickinson and traded down ($1.67) for the day and closed at $202.20Specifically, insider Stephen Sichak sold 11,787 shares of the stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the completion of the transaction, the insider now directly owns 14,038 shares in the company, valued at approximately $2,814,057.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gary M. Cohen sold 15,512 shares of the stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the transaction, the insider now owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The disclosure for this sale can be found here. Insiders have sold a total of 75,904 shares of company stock valued at $15,242,688 over the last quarter. Corporate insiders own 1.40% of the company’s stock.

A number of research firms have recently commented on BDX. BidaskClub upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a research report on Monday, August 14th. Cowen and Company reiterated an “outperform” rating and set a $230.00 target price (up from $200.00) on shares of Becton, Dickinson and in a research report on Monday, July 10th. Barclays PLC reiterated an “equal weight” rating and set a $210.00 target price (up from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price for the company in a research report on Monday, July 17th. Finally, Raymond James Financial, Inc. upgraded Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and lowered their target price for the company from $210.00 to $180.00 in a research report on Friday, June 30th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Becton, Dickinson and currently has an average rating of “Buy” and an average price target of $196.93.

The company has a market capitalization of $44.74 billion, a P/E ratio of 56.94 and a beta of 1.06. The stock has a 50 day moving average price of $199.98 and a 200 day moving average price of $191.16.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm’s quarterly revenue was down 5.1% on a year-over-year basis. During the same period in the prior year, the business earned $2.35 EPS. Analysts anticipate that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be issued a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 1.49%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s payout ratio is currently 83.43%.

A number of large investors have recently modified their holdings of BDX. BlackRock Inc. grew its holdings in Becton, Dickinson and by 2,427.8% in the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after buying an additional 15,887,611 shares in the last quarter. Koch Industries Inc. grew its holdings in Becton, Dickinson and by 45,268.7% in the 2nd quarter. Koch Industries Inc. now owns 1,398,264 shares of the medical instruments supplier’s stock valued at $1,391,000 after buying an additional 1,395,182 shares in the last quarter. Vanguard Group Inc. grew its holdings in Becton, Dickinson and by 8.5% in the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after buying an additional 1,353,780 shares in the last quarter. Winslow Capital Management LLC purchased a new stake in Becton, Dickinson and in the 2nd quarter valued at $225,164,000. Finally, Janus Henderson Group PLC grew its holdings in Becton, Dickinson and by 1,265.9% in the 2nd quarter. Janus Henderson Group PLC now owns 1,210,837 shares of the medical instruments supplier’s stock valued at $236,245,000 after buying an additional 1,122,191 shares in the last quarter. Institutional investors own 87.43% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/09/13/investors-buy-shares-of-becton-dickinson-and-company-bdx-on-weakness-on-insider-selling.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.